[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562836":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":50,"collaborators":52,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Autologous hematopoietic stem cell transplantation combined with CD19-CART","EXPERIMENTAL",null,[13],"Biological: Autologous hematopoietic stem cell transplantation combined with CD19-CART",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"erlie EL Jiang","CONTACT","+86-15122538106","jiangerlie@ihcams.ac.cn",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"NO.288 Nanjing Road，Heping District，Tianjin, Tianjin,","RECRUITING","Tianjin","Tianjin Municipality","300000","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.17667,39.14222,{"lat":38,"lon":37},[41,44,47],{"name":42,"role":22,"phone":23,"phoneExt":43,"email":24},"erlie EL Jiang, Doctor","022-23608602",{"name":45,"role":22,"phone":46,"phoneExt":43,"email":11},"rongli RL zhang","+86-13194633608",{"name":48,"role":49,"phone":11,"phoneExt":11,"email":11},"erlie EL jiang, Doctor","PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[53],{"name":54,"class":55},"Juventas Cell Therapy Ltd.","INDUSTRY","100562836","phase-2-autologous-hematopoietic-stem-cell-transplantation-combined-with-cd19-cart-treatment-of-adult-high-risk-acute-lymphoblastic-leukemia-100562836",false,"NCT06608342","Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia","Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Adult patients with high-risk acute B-lymphoblastic leukemia\n* Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared\n* Eligible for autologous hematopoietic stem cell transplantation\n* No major organ dysfunction\n\nExclusion Criteria:\n\n* Combined with malignant tumors of other organs\n* With a serious infection that is not under control\n* Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive\n* Patients who have had an allergic reaction to the drugs used in this study or similar drugs\n* Other patients deemed unsuitable for inclusion by the investigators","ALL","18 Years","65 Years",{"count":67,"type":68},20,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.",[74],"Acute Lymphoblastic Leukemia ALL",[76,77],"inaticabtagene autoleucel","auto-HSCT","2024-09-19",{"date":80,"type":81},"2024-09-23","ACTUAL",{"date":83,"type":81},"2024-06-25",{"date":85,"type":68},"2028-05-30",{"name":5,"class":6},1]